T-Cypher Bio Limited

Company description

T-Cypher Bio develops TCR (T-Cell Receptor) discovery software designed to identify TCRs for the treatment of tumours and other diseases.

We are a peptide display company identifying potential peptide drugs for a range of chronic diseases Peptides offer the potential to make drugs with the specificity and efficacy of large biologic molecules combined with the smaller dose size, simpler routes of delivery and lower cost of manufacturing found with small molecules. They are, therefore, uniquely suited to the treatment of chronic diseases which impact large patient populations. Our technology supports all of the improvements that can be made to peptides which make them better drugs whilst simplifying the discovery process and accelerating drug development. Peptides have the specificity of antibodies, manufacturing costs analogous to small molecules and simple, safe degradation products. They offer the best of both. Technologies like the Orbit method allow us to identify novel peptides as drug leads for a wide range of indications where peptides haven't previously been seen.

Tcypherbio generates TCR-based therapeutics that have the potential to transform the treatment of solid tumours, autoimmune, inflammatory, and infectious diseases. Their discovery platform generates target screening libraries to identify functionally defined T-cell clones directly from disease tissues, forming the foundation of their expanding pipeline.

Project impact

successful fund raising, and recruitment of executive team and staff

x